Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hope for the Too-Sick-for-Trials: new drug tested in frailest lung cancer patients

NCT ID NCT04108026

Completed Disease control Sponsor: Intergroupe Francophone de Cancerologie Thoracique Source: ClinicalTrials.gov ↗

Summary

This study tested the safety and effectiveness of the immunotherapy drug durvalumab in a group of patients often excluded from cancer trials: those with advanced lung cancer who were too frail for standard chemotherapy. It enrolled 50 treatment-naive patients with stage IV non-small cell lung cancer who had poor physical health scores (ECOG 2-3) but high levels of a specific biomarker (PD-L1). The goal was to see if this drug could help control their disease and improve survival with manageable side effects.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER STAGE IV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • AP-HM Hopital Nord

    Marseille, France

  • AP-HP Hopital Tenon - Pneumologie

    Paris, 75020, France

  • Besançon - CHU

    Besançon, France

  • CH

    Colmar, France

  • CHR d'Orléans La Source

    Orléans, France

  • CHRU Grenoble

    Grenoble, France

  • CHRU de Lille

    Lille, France

  • CHU Strasbourg

    Strasbourg, France

  • CHU Toulouse - Pneumologie

    Toulouse, France

  • CHU Tours - Pneumologie

    Tours, France

  • Caen - CHU Côte de Nacre

    Caen, 14000, France

  • Centre Hospitalier - Pneumologie

    Le Mans, 72000, France

  • GRH Mulhouse Sud-Alsace

    Mulhouse, France

  • Hôpital Ambroise Paré - Pneumologie

    Boulogne, France

  • Lyon - URCOT

    Pierre-Bénite, France

  • Montpellier - CHRU

    Montpellier, 34295, France

  • Nancy - Institut de Cancérologie de Lorraine

    Nancy, France

  • Nantes - ICO Site René Gauducheau

    Nantes, 44805, France

  • Paris - APHP Bichat

    Paris, France

  • Paris - Curie

    Paris, France

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CANCER STAGE IV